Stock Analiz

RxSight, Inc. RXST

Ophthalmic Goods · IPO 2021 · data as of November 13, 2026

$5.32Market cap $223M
Open the interactive analysis →

RxSight, Inc. (RXST) is a healthcare company listed in the US with a market value of about $223M. In the twelve months to September 30, 2026 it had revenue of $122M and net income of -$53M, a net margin of -43.8%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).

Key numbers: a price to free cash flow of 12.0, 5-year revenue growth of 56% a year, a 5-year average ROIC of -21%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 79% below the current price.

About RxSight

RxSight is listed in the US and classified in ophthalmic goods, IPO year 2021. Revenue went from $15M in 2020 to $134M in 2025, growth of about 55.7% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 48% over three years (dilution for shareholders). It spends 29% of revenue on research and development.

Score: 1.8 / 5

Value1/5
Future growth3/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/FCF below 20
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF12.0
P/S1.8
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield8.4%
Shareholder yield0.0%
Intrinsic value vs. price−79%

Growth and quality

Revenue growth (1 yr)-3.9%
Revenue growth (5 yrs, per year)55.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-91.0%
ROIC (5-yr avg.)-21.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$122M$134M$140M$89M$49M$23M$15M
Net income-$53M-$39M-$27M-$49M-$67M-$49M$28M
Free cash flow$19M-$19M-$22M-$46M-$61M-$47M-$38M
EPS (diluted)$-1.28$-0.95$-0.71$-1.41$-2.41$-3.57$0.15
Net margin-43.8%-29.0%-19.6%-54.6%-136.2%-215.5%187.9%
ROIC—-13.3%-9.9%-24.2%-37.1%-22.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $6.10, 15% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Hold”; expected EPS is $-0.13 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is RxSight stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 79% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does RxSight pay a dividend?

Not currently.

Is RxSight a good stock to buy?

We do not give buy or sell advice. RxSight scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.